CoChat

Nitric oxide: an ubiquitous messenger

Berdeaux, A. · 1993 · Fundamental & Clinical Pharmacology
Cited by 102

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Summary— During the last decade, a multitude of experimental arguments have led to the concept that EDRF is nitric oxide (NO), a messenger not only involved in the control of vasomotor tone but also in vascular homeostasis, neuronal and immunological functions. Regardless of its origin, endogenous NO is produced through the conversion of L‐arginine to L‐citrulline by NO‐synthase (NOS) from which several isoforms have recently been isolated, purified and cloned. NOS‐type I (isolated from brain) and type III (isolated from endothelial cells) are termed “constitutive‐NOS” and produce picomolar levels of NO from which only a small fraction elicits physiological responses. These isoforms are regulated by Ca 2+‐calmodulin with NADPH, FAD/FMN and tetrahydrobiopterin as co‐factors and reveal a high degree of homology with the amino‐acid sequence of cytochrome P450 reductase within the C‐terminal domain. Functionally, neuronal‐NOS type I is important in neurotransmission (modulation of NMDA receptor), the central control of vascular homeostasis and possibly learning and memory. In the peripheral nervous system, NOS appears to be linked to nonadrenergic noncho‐linergic (NANC) neuronal pathways. Endothelial‐NOS type III is essential for the control of vascular tone in response to the release of endogenous mediators, although shear stress is the major trigger of endothelial‐NOS activity under physiological conditions. NOS‐type III also contributes to the prevention of abnormal platelet aggregation. NOS‐types II and IV (isolated from macrophages) are Ca 2+‐calmodulin independent and are termed “inducible‐NOS” since their activation is only promoted under pathophysiological situations where macrophages exert cytotoxic effects in response to cytokines. In contrast with NOS‐types I and III, activation of NOS‐type II in these cells induces the formation of nanomolar levels of NO which act as a defense mechanism of the immune system. Dysfunctions of the L‐arginine‐NO pathway have been characterized in multiple diseases (atherosclerosis, hypertension, diabete, sepsis, cerebral ischemia, etc) and the design of more selective activators/inhibitors of NOS isoforms is a new challenge for the understanding of their pathophysiology and treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1472-8206.1993.tb01037.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 102

Metadata

Authors
Berdeaux, A.
Venue
Fundamental & Clinical Pharmacology
Publisher
Wiley
Published
1993-11
Volume
7
Issue
8
Pages
401-411
ISSN
  • 0767-3981 (ISSN-L)
  • 1472-8206
OpenAlex
W2038910005
Cited by
102
References
4
FWCI
3.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nitric oxide: an ubiquitous messenger. https://app.cochat.ai/papers/10.1111/j.1472-8206.1993.tb01037.x
The paper
Berdeaux, A. (1993). Nitric oxide: an ubiquitous messenger. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/j.1472-8206.1993.tb01037.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.